logo
logo
Sign in

Prime Healthcare Participating in Program for Promising COVID-19 Treatment

avatar
erica mary
Prime Healthcare Participating in Program for Promising COVID-19 Treatment

One of the most promising treatments for COVID-19 is being made available through an expanded access program at Prime Healthcare's Saint Michael's Medical Center in Newark.

Remdesivir, considered by the World Health Organization to be the most promising drugs to treat COVID-19, was developed by Gilead Sciences to treat Ebola. The antiviral drug is effective against two other coronaviruses that cause deadly respiratory diseases – SARS and MERS – and is in five large clinical trials for the treatment of COVID-19.

Saint Michael's is one of only a handful of sites in the world to participate in the expanded access program, which will allow the hospital to administer remdesivir to critically ill patients who are on ventilators. The hospital has been a leader in clinical infectious disease research and has worked with Gilead since the pharmaceutical company was founded in 1987.

collect
0
avatar
erica mary
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more